Furthermore, inhibition of RANKL by OPG promotes prostate cancer cell survival through inhibition of TNF-related apoptosis-inducing ligand (TRAIL)-mediated apoptosis [77]. The gene discussed is TNFSF11; the disease is prostate carcinoma.